Rezolute (RZLT) Income towards Parent Company (2012 - 2026)
Rezolute (RZLT) posted Income towards Parent Company of -$20.9 million for Q1 2026, up 17.2% sequentially from -$25.3 million in Q4 2025, and up 13.68% YoY from -$18.4 million in Q1 2025.
Rezolute (RZLT) Income towards Parent Company (2012 - 2026) Analysis & Trends
Rezolute has reported Income towards Parent Company for 15 years, with the latest figure at -$20.9 million in Q1 2026.
- Quarterly Income towards Parent Company rose 13.68% year-over-year to -$20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163.3 million (down 43.66% YoY) and the FY2025 annual result came in at -$164.3 million, down 105.04% from the prior year.
- Income towards Parent Company climbed to -$20.9 million in Q1 2026 per RZLT's latest filing, from -$25.3 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$10.0 million in Q3 2022 and troughed at -$92.5 million in Q3 2025.
- A 5-year average of -$23.7 million and a median of -$19.8 million in 2024 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 27.66% in 2025, down 158.47% in 2025.
- Over 5 years, Income towards Parent Company stood at -$14.1 million in 2022, then fell by 0.68% to -$14.2 million in 2023, then tumbled by 145.39% to -$34.9 million in 2024, then climbed by 27.66% to -$25.3 million in 2025, then increased by 17.2% to -$20.9 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$20.9 million, -$25.3 million, and -$92.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.93 Mn |
| Dec 31, 2025 | -25.27 Mn |
| Sep 30, 2025 | -92.46 Mn |
| Jun 30, 2025 | -24.59 Mn |
| Mar 31, 2025 | -24.24 Mn |
| Dec 31, 2024 | -34.94 Mn |
| Sep 30, 2024 | -35.77 Mn |
| Jun 30, 2024 | -18.69 Mn |
| Mar 31, 2024 | -19.84 Mn |
| Dec 31, 2023 | -14.24 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -10.03 Mn |
| Mar 31, 2023 | -20.21 Mn |
| Dec 31, 2022 | -14.14 Mn |
| Sep 30, 2022 | -9.99 Mn |
| Jun 30, 2022 | -11.71 Mn |
| Mar 31, 2022 | -11.45 Mn |
| Dec 31, 2021 | -12.84 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -6.66 Mn |